ZGNX

FINTEPLA (ZX008)

Dravet syndrome

Quarterly Sales (Approved)

Exp Date

August 5, 2020

Amp Volatility Score

Catalyst Info & Data Links

POSTERS


PRESENTATIONS


PUBLICATIONS





COMPETITORS

  • Anticonvulsant

          DIACOMIT® (stiripentol) 

  • Cannabidiol:

          Epidyolex®

                    GW Pharmaceuticals Published Data

MARKET

MECHANISM OF ACTION/RATIONALE

  • Fintepla is Fenfluramine (2.2 mg/mL)

  • Fintepla has a novel mechanism of action (selective serotonin activity and possibly sigma-1 activity). (See details)

  • In addition to its serotonergic effects, also exhibits activity at the sigma-1 receptor.  Fenfluramine acts as a positive allosteric modulator of the receptor. (See details)

 

Updated by MV

#ZGNX, #FINTEPLA, #ZX008, #dravet_syndrome,

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Jackpot...

BINGO #winner #ZGNX #AMRN #AIMT...

ZGNX Fintepla approved for Dra...

Congrats to ZGNX on FDA approval of Fintepla for Dravet (See our AmpCard https://bit.ly/3evfnLU for published data & more). It will be interesting to see how well it competes with GWPH EPIDOLEX. Will ...

[DD Example] Zogenix: Major Up...

#ZGNX #LGS #Phase3 This is an example of what you can find in our Deeper Diligence channel here. You can access these deeper diligence articles by becoming a free member today, just click "Sign Up" i...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon